Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloctate vs Emicizumab in Severe Hemophilia A
NCT04303559Phase 3Terminated
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of emicizumab in hemophilia A. Started Oct 2021; status: terminated.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04303559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303559.